Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In trading on Friday, shares of Marine Products Corp. ( MPX - Get Report) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $5.92 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 50.8. A bullish investor could look at MPX's 29.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of MPX shares: Looking at the chart above, MPX's low point in its 52 week range is $5.87 per share, with $8.99 as the 52 week high point — that compares with a last trade of $5.87.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Financial Market Behavior, General Mills Earnings: Market Recon
Markets must choose now between the easy, the tense and the uncertain. What could possibly go wrong?
Del Frisco's to Be Acquired for $650 Million by Private-Equity Firm L Catterton
Del Frisco's is being acquired by private-equity firm L Catterton for $8 a share.
Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
Bristol-Myers Squibb shares slumped lower in pre-market trading Monday after the group said the U.S. Federal Trade Commission was still looking into its proposed $74 billion takeover of cancer specialist Celgene and that it would sell that company's psoriasis to push the deal through.